Wolf Theiss has advised Euronext Amsterdam-listed Royal DSM on its acquisition of the Erber Group, an animal nutrition and health business. Closing is contingent on customary conditions.
Wolf Theiss describes DSM Koninklijke DSM N.V. as "a Dutch multinational corporation active in the fields of health, nutrition, and materials, [that is] headquartered in Heerlen [and] employs around 23,000 people in approximately 50 countries." According to the firm, "DSM provides nutritional solutions for animal health and human well-being, serving the global feed, food & beverage, pharmaceutical, infant nutrition, dietary supplements, and personal care industries.”
Wolf Theiss’ team included Partners Florian Kusznier, Markus Bruckmueller, Guenter Bauer, Kurt Retter, and Karl Binder, Senior Associate Zeno Grabmayr, and Associates Martina Hiebl, Lukas Slameczka, and Simona Shpilsky.
Wolf Theiss did not reply to our inquiry on the matter.
Editor's note: After this article was published CEE Legal Matters learned that Cerha Hempel had advised San Pacific Investment and San Venture Biotech, as well as their sole shareholder Erich Erber, the founder of Erber AG, on the sale of Erber to Royal DSM.
Cerha Hempel's team included Managing Partner Albert Birkner, Partner Bernhard Kofler-Senoner, Senior Counsel Johannes Buchinger, Counsels Wolfgang Sindelar, Michael Mayer, Armin Schwabl, and Katharina Majchrzak, Senior Associates Nadine Leitner, Martin Eichinger, Christopher Peitsch, and Franziska Paefgen, and Associates Alistair Gillespie, Jakob Weber, Zakar Stepanyan, Philipp Schaubach, and Ludwig Hastermann.
Subsequently, on October 5, 2020, Cerha Hempel announced that the deal "has now been successfully completed following approval by the competent competition authorities and the carve-out of the SANPHAR and EFB divisions. According to the firm, Cerha Hempel Partner Albert Birkner assisted "with the acquisition of the SANPHAR and EFB divisions from Erber AG and for obtaining the approval of the competent competition authorities."